한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제20권2호
  • /
  • Pages.138-144
  • /
  • 2010
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지

Venlafaxine의 안면홍조 증상개선효과에 대한 최근 연구 고찰

Venlafaxine for Management of Hot Flashes: A Review of Randomized Controlled Trials in Human

  • 이유정 (숙명여자대학교 임상약학대학원)
  • Lee, Yu-Jeung (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
  • 투고 : 2010.07.02
  • 심사 : 2010.08.13
  • 발행 : 2010.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

안면홍조는 폐경기 초기 많은 여성들에게 나타나는 증상이다. 정확한 원인은 밝혀지지 않았지만 혈중 에스트로겐 수치가 낮아졌을 때 안면홍조 증상이 나타나기 때문에 에스트로겐을 기본으로 한 호르몬 요법이 수년간 안면홍조 증상치료의 중심이었다. 그러나 호르몬 요법이 유방암, 뇌졸중 등의 발생 위험도를 증가시킨다는 연구 결과가 발표된 이후 많은 보건의료인들은 호르몬 요법 대신 사용 가능한 다른 치료제에 관심을 보이고 있다. 본 연구는 venlafaxine의 안면홍조 증상 치료효과에 대한 최신 지견을 얻고자, 1990년부터 2010년 7월까지 MEDLINE에 등재된 논문을 Hot flashes와 Venlafaxine이라는 MeSH terms로 검색하여 추출한 자료 중에서 대조군이 사용된 무작위 배정 및 이중맹검 임상연구 사례만을 선별하여 임상적 유용성을 평가하였다. 현재 venlafaxine은 안면홍조 증상 치료제로 허가된 의약품은 아니지만 최근 여러 국가에서 시행된 연구들은 venlafaxine이 효과적인 안면홍조 증상 치료제일 수 있다는 결과를 보여주고 있다.

The results from eight randomized controlled studies demonstrate that venlafaxine is effective in the treatment of hot flashes with tolerable adverse effects. Based on the results of the above studies, venlafaxine can be recommended for the treatment of hot flashes. However, there are limitations in the above studies. The inclusion criteria of 5 studies reviewed in this paper was breast cancer patients, so it's hard to apply the results to the general population in clinical practice. Also 5 studies had less than 100 subjects included, and 18-week study was the longest one among studies reviewed in this paper. Therefore, large and long-term clinical studies with the general population should be conducted to use venlafaxine for the treatment of hot flashes in clinical practice.

키워드

참고문헌

  1. Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000; 36: 155-164. https://doi.org/10.1016/S0378-5122(00)00151-1
  2. Mohyi D, Tabassi K, Simon J. Differential diagnosis of hot flashes. Maturitas 1997; 27: 203-214. https://doi.org/10.1016/S0378-5122(97)83974-6
  3. Kronenberg F, Downey J. Thermoregulatory physiology of menopausal hot flashes. Canadian J Physiol Pharmacol 1987; 65: 1312-1322. https://doi.org/10.1139/y87-208
  4. Rossouw JE, Anderson GL, Prentice RL, et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333. https://doi.org/10.1001/jama.288.3.321
  5. Lomax P, Schonbaum E. Postmenopausal hot flushes and their management. Pharm Ther 1993; 57: 347-358. https://doi.org/10.1016/0163-7258(93)90060-Q
  6. Freedman RR, Woodward S, Sabharwal SC. Alpha 2-adrenergic mechanism in menopausal hot flushes. Obstet Gynecol 1990; 76: 573-578.
  7. $Effexor^{\circledR}$ prescribing information. Wyeth Pharmaceuticals. 2009.
  8. Venlafaxine hydrochloride. In: AHFS Drug Information. American Society of Health-System Pharmacists. 2010.
  9. Venlafaxine. In: Drug Information Handbook. Lexi-$Comp^{\circledR}$. 2008.
  10. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000; 57: 503-509. https://doi.org/10.1001/archpsyc.57.5.503
  11. Tran PV, Bymaster FP, McNamara RK, et al., Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003; 23: 78-86. https://doi.org/10.1097/00004714-200302000-00011
  12. Loprinzi CL, Kugler JW, Sloan JA, et al., Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356: 2059-2063. https://doi.org/10.1016/S0140-6736(00)03403-6
  13. Evans ML, Pritts E, Vittinghoff E, et al., Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005; 105: 161-166. https://doi.org/10.1097/01.AOG.0000147840.06947.46
  14. Loprinzi CL, Levitt R, Barton D, et al., Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol 2006; 24: 1409-1414. https://doi.org/10.1200/JCO.2005.04.7324
  15. Carpenter JS, Storniolo AM, Johns S, et al., Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist 2007; 12: 124-135. https://doi.org/10.1634/theoncologist.12-1-124
  16. Loibl S, Schwedler K, von Minckwitz G, et al., Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study. Ann Oncol 2007; 18: 689-693.
  17. Buijs C, Mom CH, Willemse PH, et al., Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 2009; 115: 573-580. https://doi.org/10.1007/s10549-008-0138-7
  18. Irani J, Salomon L, Oba R, et al., Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010; 11: 147-154. https://doi.org/10.1016/S1470-2045(09)70338-9
  19. Walker EM, Rodriguez AI, Kohn B, et al., Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 2010; 28: 634-640. https://doi.org/10.1200/JCO.2009.23.5150